Background: Ivacaftor increases CFTR channel activity and improves pulmonary function for individuals bearing a G551D mutation. Because ivacaftor structurally resembles quinolone antibiotics, we tested the hypothesis that ivacaftor possesses antibacterial properties. Methods: Bioluminescence, colony forming unit, and minimal inhibitory concentration assays were used to assess viability of Staphylococcus aureus, Pseudomonas aeruginosa and multiple clinical microbial isolates. Results: Ivacaftor induced a dose-dependent reduction in bioluminescence of S. aureus and decreased the number of colony forming units. We observed a similar but less robust effect in P. aeruginosa following outer membrane permeabilization. Ivacaftor inhibited the growth of respiratory isolates of S. aureus and Streptococcus pneumoniae and exhibited positive interactions with antibiotics against lab and respiratory strains of S. aureus and S. pneumoniae. Conclusion: These data indicate that ivacaftor exhibits antibacterial properties and raise the intriguing possibility that ivacaftor might have an antibiotic effect in people with CF.
Introduction
Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF), a life-shortening autosomal recessive disease. Airway infections are a prominent feature of CF and they reduce lung function [1] . Ivacaftor (VX-770, Kalydeco) is a CFTR potentiator that enhances CFTR activity by directly targeting the channel, increasing its open state probability, and thereby improves pulmonary function [2, 3] . The chemical structure of ivacaftor bears a quinoline ring. Because many quinoline derivatives (such as quinolone antibiotics) have antimicrobial activity [4] , we tested the hypothesis that ivacaftor might possess antibacterial properties.
Materials and methods

Drugs
Ivacaftor was purchased from Selleckchem (cat. #S1144) and dissolved in 50% DMSO. Ceftriaxone sodium salt (Sigma, C5793), vancomycin hydrochloride (Sigma V-2002), moxifloxacin hydrochloride (Sigma 32477), trimethoprim (Sigma T7883), sulfamethoxazole (Sigma S-7507), linezolid (Sigma PZ0014), and ciprofloxacin (Sigma 17850) were prepared according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [5] .
Bacteria
CLSI-recommended quality control strains for Streptococcus pneumoniae (ATCC 49619) and Staphylococcus aureus (ATCC 29213) were purchased through Remel. Lower respiratory clinical isolates of S. aureus (MSSA and MRSA) and S. pneumoniae were obtained from The University of Iowa 2011 and 2010 national surveillance study, respectively. For bioluminescent assays, S. aureus Xen29 strain [6] and Pseudomonas aeruginosa expressing the lux operon were used. Briefly, pUCP19lux was constructed by cloning the lux operon from mini-CTX-lux [7] into the multiple cloning site of the pUCP19 expression vector [8] . P. aeruginosa strain PA103 was transformed with pUCP19lux and maintained under carbenicillin selection.
Bioluminescence measurements
Studies were performed as described previously [6] . Briefly, mid log-phase bacteria were resuspended in 1% Tryptic Soy Broth medium with 10 mM potassium phosphate buffer (pH 7.4) to reach a desired inoculum of 5 × 10 4 CFU. For permeabilization experiments, P. aeruginosa was incubated in 0.2 mM EDTA at pH 8.0 for 15 min [9] and immediately centrifuged and resuspended in 1% Tryptic Soy Broth medium with 10 mM potassium phosphate buffer (pH 7.4). Bacteria were incubated in indicated concentrations of ivacaftor or antibiotic in 96-well plates (Optiplate-96, PerkinElmer) in a total volume of 100 μl. Controls were the same conditions in the same plates, but contained vehicle (5% DMSO) only. Fig. 1 . Antibacterial properties of ivacaftor. A) Ivacaftor induced a dose-dependent reduction in bioluminescence of S. aureus; n = 8. B) Dose response of ivacaftor (n = 8), vancomycin (n = 4) and vancomycin + 1 μg/ml ivacaftor (n = 4) at 30 min. Data are normalized to vehicle controls; *P ≤ 0.05 compared to vancomycin only. C) Incubation of S. aureus with ivacaftor (iva), vancomycin (vanc.) or vancomycin + 1 μg/ml ivacaftor (iva + vanc.) for 120 min resulted in a reduction in the number of CFUs. The number following the label indicates the dose in μg/ml; n = 4 experiments; *P ≤ 0.05 compared to vancomycin (0.07 μg/ml), # compared to ivacaftor (1 μg/ml). D) Ivacaftor induced a dose-dependent reduction in bioluminescence of P. aeruginosa permeabilized with 0.2 mM EDTA; n = 5 experiments. E) Dose response of ivacaftor (n = 5 experiments), ciprofloxacin (n = 3 experiments) and ciprofloxacin + 1 μg/ml ivacaftor (n = 3 experiments) at 60 min. *P ≤ 0.05 compared to ciprofloxacin only. Data are normalized to vehicle controls. F) Incubation of P. aeruginosa with ivacaftor (iva), ciprofloxacin (cip.) or ciprofloxacin + 1 μg/ml ivacaftor (iva + cip.) for 120 min reduced the number of CFUs. The number following the label indicates the dose in μg/ml. For vehicle, n = 5; ivacaftor 1 μg/ml, n = 4; ivacaftor 32 μg/ml, n = 5; ciprofloxacin 0.0009 μg/ml, n = 3; ciprofloxacin 32 μg/ml, n = 3. Because in permeabilized P. aeruginosa, even very low doses of ciprofloxacin markedly decreased CFUs, we do not report the combination of ivacaftor and ciprofloxacin.
Luminescence was measured with a luminometer (SpectraMax L, Molecular Devices).
CFU assays
S. aureus or P. aeruginosa was incubated with antibiotic or ivacaftor in minimal growth conditions at designated doses for 2 h. The number of CFUs was determined as previously described [6] .
Susceptibility testing
Minimum inhibitory concentrations (MIC) were determined using the CLSI broth microdilution susceptibility testing method [5] . Samples were run in duplicate on two separate occasions.
Statistics
Results are expressed as mean ± SEM. For bioluminescence assays, a two-way ANOVA (to test time and treatment) was performed with a post-hoc Bonferroni test. For CFU assays, a subgroup one-way ANOVA (to test treatment) with post-hoc Bonferroni test was performed. P ≤ 0.05 was considered to be statistically significant.
Results
To investigate whether ivacaftor possesses antibacterial properties, we utilized three different tests of bacterial viability, including bioluminescence, colony forming unit (CFU) and minimal inhibitory concentration (MIC) assays. For the bioluminescence and CFU assays, we focused on S. aureus and P. aeruginosa, two important pathogens in CF airway disease [1, 10] . With the MIC assays, we tested multiple clinical microbial isolates in addition to S. aureus and P. aeruginosa.
S. aureus is one of the first organisms to infect CF airways [1, 10] . We utilized a bioluminescent strain of S. aureus and found that ivacaftor induced a dose-dependent and rapid reduction in bioluminescence (Fig. 1A, B) , suggesting a reduction in bacterial viability. The ivacaftor-induced reduction in bioluminescence was similar to that observed with vancomycin, an antibiotic used to treat S. aureus infections [11] (Fig. 1B) . We also asked whether the combination of ivacaftor and vancomycin was more effective at reducing bioluminescence than either drug alone. To test this, we added ivacaftor at a concentration achieved in the serum of people with CF (1 μg/ml) [12] , and found that it increased vancomycin's activity (Fig. 1B) .
Reductions in bioluminescence have an excellent correlation with a decrease in CFU [13] . Accordingly, we observed decreased CFU in conditions matching our bioluminescent assays (Fig. 1C) . We also tested whether the combination of sub-inhibitory doses of ivacaftor and vancomycin was more effective than either drug alone. Indeed, we found that pairing sub-inhibitory doses of ivacaftor with vancomycin reduced CFU more than either drug independently (Fig. 1C) .
Because P. aeruginosa also frequently infects CF airways [1], we asked whether ivacaftor had antibacterial properties against it. We utilized a bioluminescent strain of P. aeruginosa and discovered that ivacaftor only mildly decreased bioluminescence (Supplemental Fig. 1 ). Previous studies indicate that the outer membrane of P. aeruginosa limits the diffusion of hydrophobic substances, including antibiotics [14] . Therefore, we hypothesized that the outer membrane of P. aeruginosa might serve as a barrier for ivacaftor penetration. To test this hypothesis, we permeabilized the outer membrane with 0.2 mM EDTA for 15 min [9, 15] . After permeabilization, we observed a dose-dependent reduction in bioluminescence with ivacaftor (Fig. 1D, E) . The drop in bioluminescence was similar to that observed with the antibiotic ciprofloxacin, although ivacaftor was less effective than ciprofloxacin at low doses. We also added ivacaftor at a pharmacologically relevant concentration of 1 μg/ml [12] to ciprofloxacin and found that it increased ciprofloxacin's potency (Fig. 1E) . However, CFU assays of P. aeruginosa after 15 min of permeabilization revealed that ivacaftor only modestly reduced CFUs at the highest concentration (Fig. 1F) . This was in contrast to ciprofloxacin, which exhibited robust activity against permeabilized P. aeruginosa at both high and low doses (Fig. 1F ). Thus, it is possible that the bioluminescence assay using EDTA-pretreated P. aeruginosa might not accurately reflect viability.
We also tested ivacaftor using the highly standardized CLSI broth dilution MIC assay and discovered that ivacaftor inhibited the growth of laboratory and clinical respiratory isolates of S. aureus (MRSA and MSSA) and S. pneumoniae (Table 1) . However, the maximum tested dose of ivacaftor (32 μg/ml due to solubility limitations) was not effective at inhibiting growth of all the gram-positive species examined (Table 1 ). Additionally we were not able to establish MICs for any of the gram-negative species tested; this is consistent with Table 1 MICs of ivacaftor for multiple bacterial species. (+) = gram-positive; (−) = gram-negative.
Species
Ivacaftor MIC (μg/ml) 
the low activity of ivacaftor on P. aeruginosa and also with the requirement for outer membrane permeabilization (Table 1) . People with CF are often treated with antibiotics [16, 17] , and thus there is a possibility for a beneficial interaction with ivacaftor. We therefore asked whether ivacaftor might display positive interactions with other antibiotics, thereby suggesting additivity or synergy. We used checkerboard-type drug combination MIC assays and found positive interactions of ivacaftor with ceftriaxone, a broad-spectrum cephalosporin antibiotic [18] , against a clinical isolate of S. pneumoniae and a lab strain and clinical isolate of S. aureus (methicillin-sensitive S. aureus, MSSA) (Table 2) . Similarly, we observed positive interactions of ivacaftor against a respiratory isolate of S. pneumoniae and a lab strain of S. aureus when used in combination with vancomycin. The combination of ivacaftor with trimethoprim-sulfamethoxazole (Table 2) , an antibiotic commonly used to treat S. aureus [19] , also revealed positive interactions against a clinical strain of S. pneumoniae and against lab and clinical strains of S. aureus (MRSA). Additional positive interactions were observed with moxifloxacin (a broad spectrum fluoroquinolone), and linezolid (an oxazolidinone indicated for gram-positive bacteria [11] against lab strains of S. aureus and against lab and respiratory isolates of S. pneumoniae (Table 2) ).
Discussion
Using three different assays, we found that ivacaftor possesses antibacterial properties. Moreover, we found positive interactions of ivacaftor with other antibiotics suggestive of additivity or synergy. Thus, our data indicate that ivacaftor, a drug that increases CFTR channel activity, exhibits antibiotic qualities. Although the mechanism by which ivacaftor reduces bacterial viability is unknown, our data are consistent with the hypothesis that the quinoline ring of ivacaftor might impart an antibiotic property. However, our data do not reveal broad-spectrum activity expected from a traditional quinolone antibiotic. For example, typically quinolones are effective against gramnegative bacteria-our studies with ciprofloxacin were consistent with this-yet with ivacaftor we only observed a minimal effect. However, structural modifications of fluoroquinolones can in some cases enhance activity against gram-positive bacteria [20] . Therefore, perhaps ivacaftor's structure has enabled more selectivity against gram-positive microbes compared to gram-negative microbes. If true, this property is consistent with other reported modifications of quinoline derivatives and the subsequent effect on antibacterial activity [21] .
Our findings raise the question of whether or not ivacaftor might possess antibiotic-like properties in vivo. We observed anti-Staphylococcal activity of ivacaftor at 2.0 μg/ml in the bioluminescence assay, minimal activity at 1.0 μg/ml in the CFU assays, and robust activity at 8.0 μg/ml in the MIC assays. This compares to circulating ivacaftor levels of~1.4 μg/ml after five days of treatment [12] . However, steady state levels of ivacaftor following prolonged treatment are unknown. Further, as is observed with quinolones, concentrations of ivacaftor in the airway surface liquid might be substantially higher than circulating levels [22] . In addition, positive interactions of ivacaftor with other antibiotics at doses achievable in vivo suggests that there might be a beneficial interaction of ivacaftor with other antibiotics. This possibility may have some credence given the abundance of antibiotics utilized in people for the treatment of CF. Although our in vitro studies do not answer questions about in vivo antibacterial activity, the data and these considerations raise an intriguing possibility.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.jcf.2014.02.004.
